{
    "ticker": "BDSX",
    "name": "BioDelivery Sciences International, Inc.",
    "description": "BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company dedicated to the development of innovative products for the treatment of chronic pain and addiction. Founded in 2010 and headquartered in Raleigh, North Carolina, BDSI focuses on providing solutions that address significant medical needs, particularly in the areas of pain management and opioid dependence. The company\u2019s lead product, BELBUCA (buprenorphine buccal film), is a unique formulation designed to manage chronic pain in patients requiring continuous, long-term opioid therapy. BELBUCA is the first and only buprenorphine product with FDA approval for chronic pain management. Additionally, BDSI is working on expanding its product portfolio through its proprietary drug delivery technologies, such as its BioErodible Mucoadhesive (BEMA) technology, which allows for enhanced absorption and efficacy. By focusing on patient-centric solutions, BDSI aims to improve the quality of life for individuals suffering from painful conditions while also addressing the challenges associated with opioid use. The company is committed to advancing research and development in the field of pain management and addiction treatment, striving to provide healthcare professionals and patients with effective, safe, and innovative options.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Raleigh, North Carolina, USA",
    "founded": "2010",
    "website": "https://www.bdsi.com",
    "ceo": "Jeffrey P. Bailey",
    "social_media": {
        "twitter": "https://twitter.com/BioDeliverySciences",
        "linkedin": "https://www.linkedin.com/company/biodelivery-sciences-international-inc/"
    },
    "investor_relations": "https://ir.bdsi.com",
    "key_executives": [
        {
            "name": "Jeffrey P. Bailey",
            "position": "CEO"
        },
        {
            "name": "Mark A. Sirgo",
            "position": "President"
        }
    ],
    "product_categories": [
        {
            "category": "Pain Management",
            "products": [
                "BELBUCA"
            ]
        },
        {
            "category": "Opioid Dependence",
            "products": [
                "Sublocade"
            ]
        }
    ],
    "seo": {
        "meta_title": "BioDelivery Sciences International, Inc. | Innovative Pain Management Solutions",
        "meta_description": "Explore BioDelivery Sciences International, Inc., a leader in chronic pain management and addiction treatment, focusing on innovative pharmaceutical solutions.",
        "keywords": [
            "BioDelivery Sciences",
            "Chronic Pain",
            "BELBUCA",
            "Opioid Dependence",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is BioDelivery Sciences known for?",
            "answer": "BioDelivery Sciences is known for its innovative products for chronic pain management and opioid dependence."
        },
        {
            "question": "Who is the CEO of BioDelivery Sciences?",
            "answer": "Jeffrey P. Bailey is the CEO of BioDelivery Sciences International, Inc."
        },
        {
            "question": "Where is BioDelivery Sciences headquartered?",
            "answer": "BioDelivery Sciences is headquartered in Raleigh, North Carolina, USA."
        },
        {
            "question": "What are the main products of BioDelivery Sciences?",
            "answer": "The main products include BELBUCA for pain management and Sublocade for opioid dependence."
        },
        {
            "question": "When was BioDelivery Sciences founded?",
            "answer": "BioDelivery Sciences was founded in 2010."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "AMGN",
        "NVS"
    ],
    "related_stocks": [
        "ABBV",
        "VRTX",
        "REGN",
        "BMY"
    ]
}